Asia-Pacific Liquid Biopsy Market share 2021: By Growing Rate, Type, Applications, Geographical Regions Forecast To 2027

Precision Business Insights published a research report on "Liquid Biopsy Market: By-Products and Services (Instruments, Reagents, and Services & Software), By Biomarker Type (Circulating Tumor Cells (CTC), Circulating Tumor DNA (ctDNA), Exosomes, and Others), By Sample Type (Blood Samples, Urine Samples, and Other Biofluid Samples), By Application (Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, Leukemia, Lung Cancer, Prostate Cancer, and Other Cancers), By Analysis Method (Multigene – parallel Analysis and Single Gene Analysis (PCR Microarrays)), By End-User (Hospitals, Diagnostic Laboratories, and Academic and Research Institutes) and Geography - Global/Region/Country Forecast to 2027"

Liquid biopsy is a non-invasive and straightforward alternative to ‘conventional' or surgical biopsies, and it entails the collection and examination of non-solid biological matter, usually blood. Medical practitioners can use liquid biopsies to learn about various characteristics of a tumor from a patient's blood sample. Medical practitioners can use the liquid biopsy to figure out which therapies are best for the patient. In the event of patients whose tissue cannot be biopsied or as an addendum to thoroughly analyses medication response, liquid biopsies are a helpful substitute to surgical biopsies. These procedures also allow medical practitioners to acquire repeated samples during the primary treatment (which is not possible with a Tumor biopsy) in order to evaluate the tumor's development and medication sensitivity in the patient.

View Detailed Report Description at https://precisionbusinessinsights.com/market-reports/liquid-biopsy-market/

Liquid biopsy is a common and safe method used during the cancer diagnostic process. Early cancer diagnosis and screening, characterization of new lesions, and pharmacological and therapeutic target attributions for cancer therapy are some of the significant benefits of liquid biopsies, which improve the safety and effectiveness of cancer treatment, these factors on the other hand is expected to fuel the Liquid Biopsy Market in the coming years. The benefit of liquid biopsy versus solid tumor biopsy are becoming increasingly apparent as cancer rates rise. With the rising demand for non-invasive treatments, governmental and private funding for researchers in the context of liquid biopsy is expanding, which is further is expected to boost the market in the coming years. Clinical utility issues, a lack of accuracy and precision in liquid biopsy tests, and an unclear compensation and regulation situation are all contributing to the market's growth.

The Global Liquid Biopsy Market is categorized in terms of Application, Product and Service, Circulating Biomarker, Clinical Application, End-User, and Geography. On the basis of Circulating Biomarker, the global Liquid Biopsy Market has been fragmented into Circulating Tumour DNA (CTDNA), Circulating Tumour Cells (CTCs), Extracellular Vesicles (EVS), Cell-Free DNA (cfDNA), and others. On the basis of End-User, the global Liquid Biopsy Market has been divided into Hospitals and Physician Laboratories, Reference Laboratories, Academic and Research Centers, and Other. On the basis of Application, the global Liquid Biopsy Market has been segregated into Non-Cancer Applications and Cancer Applications. In terms of Product and Service, the Global Liquid Biopsy Market has been divided into Instruments, Assay Kits, and Services. In terms of Clinical Application, the global Liquid Biopsy Market has been categorized into Therapy Selection, Early Cancer Screening, Recurrence Monitoring, and Treatment Monitoring.

In 2021, Asia-Pacific had the highest market share, while North America had the second largest. Because it has evolved as a significant manufacturer and supplier of Liquid Biopsy to the worldwide, the Asia Pacific area is regarded to be the largest production hub for Liquid Biopsy.

Request sample report at https://precisionbusinessinsights.com/request-sample?product_id=17392

There are several industry players working in the liquid biopsy market, which include Biocept Inc. (U.S), Bio-Rad Laboratories Inc. (U.S), Fraunhofer-Gesellschaft (Germany), Guardant Health, Inc. (U.S), Janssen Diagnostics, LLC (U.S), MDxHealth SA (U.S), Myriad Genetics (U.S), QIAGEN (Netherlands), RainDance Technologies, Inc. (U.S), Roche (Switzerland), Trovagene Inc. (U.S)

Contact:
Mr. Satya
Precision Business InsightsTM | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 – 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.